Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)

Publikation: Bidrag til tidsskriftLetterForskningpeer review

Harvard

Jensen, J, Omar, M, Kistorp, C, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Faber, J, Forman, JL, Møller, JE & Schou, M 2021, 'Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)', Circulation, bind 143, nr. 22, s. 2208-2210. https://doi.org/10.1161/CIRCULATIONAHA.120.053463

APA

Jensen, J., Omar, M., Kistorp, C., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F., Faber, J., Forman, J. L., Møller, J. E., & Schou, M. (2021). Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). Circulation, 143(22), 2208-2210. https://doi.org/10.1161/CIRCULATIONAHA.120.053463

CBE

MLA

Vancouver

Author

Jensen, Jesper ; Omar, Massar ; Kistorp, Caroline ; Tuxen, Christian ; Gustafsson, Ida ; Køber, Lars ; Gustafsson, Finn ; Faber, Jens ; Forman, Julie L ; Møller, Jacob E ; Schou, Morten. / Metabolic Effects of Empagliflozin in Heart Failure : A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). I: Circulation. 2021 ; Bind 143, Nr. 22. s. 2208-2210.

Bibtex

@article{341d34fcab2a4e28bac6082b8a8c5ccf,
title = "Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)",
keywords = "Body composition, Diabetes mellitus, Empagliflozin, Heart failure, Insulin resistance, Sodium-glucose transporter 2 inhibitors, Type 2",
author = "Jesper Jensen and Massar Omar and Caroline Kistorp and Christian Tuxen and Ida Gustafsson and Lars K{\o}ber and Finn Gustafsson and Jens Faber and Forman, {Julie L} and M{\o}ller, {Jacob E} and Morten Schou",
year = "2021",
month = jun,
day = "1",
doi = "10.1161/CIRCULATIONAHA.120.053463",
language = "English",
volume = "143",
pages = "2208--2210",
journal = "Circulation (Baltimore)",
issn = "0009-7322",
publisher = "Lippincott Williams & Wilkins",
number = "22",

}

RIS

TY - JOUR

T1 - Metabolic Effects of Empagliflozin in Heart Failure

T2 - A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)

AU - Jensen, Jesper

AU - Omar, Massar

AU - Kistorp, Caroline

AU - Tuxen, Christian

AU - Gustafsson, Ida

AU - Køber, Lars

AU - Gustafsson, Finn

AU - Faber, Jens

AU - Forman, Julie L

AU - Møller, Jacob E

AU - Schou, Morten

PY - 2021/6/1

Y1 - 2021/6/1

KW - Body composition

KW - Diabetes mellitus

KW - Empagliflozin

KW - Heart failure

KW - Insulin resistance

KW - Sodium-glucose transporter 2 inhibitors

KW - Type 2

UR - http://www.scopus.com/inward/record.url?scp=85107052729&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.120.053463

DO - 10.1161/CIRCULATIONAHA.120.053463

M3 - Letter

C2 - 34061581

VL - 143

SP - 2208

EP - 2210

JO - Circulation (Baltimore)

JF - Circulation (Baltimore)

SN - 0009-7322

IS - 22

ER -

ID: 68355398